Adams Respiratory Therapeutics
This article was originally published in The Tan Sheet
Rx-to-OTC switch expert Bill Howard, PhD, joined Adams in the newly created post of executive director of new product development May 10. Howard reports to Robert Casale at the firm's new corporate HQ in Chester, N.J.. Most recently President of SDM switch consultancy, Howard has worked in marketing analysis and strategic planning at Miles Labs and Parke-Davis...
You may also be interested in...
Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.